Microchip Technology Inc. (MCHP) Shares Bought by New Mexico Educational Retirement Board

Lloyd Doyle
March 13, 2018

Citigroup maintained the shares of CVX in report on Monday, October 30 with "Buy" rating. At the current pps, the market capitalization stands at 23.437B. The firm has "Buy" rating by Mizuho given on Monday, March 5. The company was maintained on Friday, July 28 by Jefferies. BMO Capital Markets maintained Welltower Inc. The rating was initiated by Susquehanna on Tuesday, April 11 with "Positive". On Tuesday, September 8 the stock rating was upgraded by JP Morgan to "Overweight". The stock has "Buy" rating by Stifel Nicolaus on Sunday, October 15. On Wednesday, February 7 the stock rating was maintained by KeyBanc Capital Markets with "Hold".

Strategy Asset Managers Llc decreased Microchip Technology Inc (MCHP) stake by 10.14% reported in 2017Q3 SEC filing.

Stock of Microchip Technology Incorporated (MCHP) last opened at $99.53 and traded at $99.86 x 200. The institutional investor held 165,403 shares of the semiconductors company at the end of 2017Q3, valued at $14.85M, down from 184,072 at the end of the previous reported quarter.

Microchip Technology Incorporated (NASDAQ:MCHP), maintained return on investment for the last twelve months at 12.52, higher than what Reuters data shows regarding industry's average. The share price was last seen 3.81% higher, reaching at $98.97 on Sep.

Resonant Inc. (NASDAQ:RESN) closed up +0.17 points or 3.8% at $4.64 with 0.1 mln shares exchanging hands. It has outperformed by 51.60% the S&P500.

Analysts await Microchip Technology Incorporated (NASDAQ:MCHP) to report earnings on May, 8. Analysts are expecting that the company may be attaining earnings growth of 25.30% for next five years. MCHP's profit will be $297.62 million for 19.67 P/E if the $1.27 EPS becomes a reality. After $0.36 actual earnings per share reported by KeyCorp for the previous quarter, Wall Street now forecasts 8.33% EPS growth. It is trading at a P/S value of 0.75 and P/B registered at 1.48.

Other hedge funds have also recently added to or reduced their stakes in the company. About 133,471 shares traded. Jpmorgan Chase & holds 0.16% or 8.32 million shares in its portfolio. Investors who are keeping close eye on the stock of Windstream Holdings, Inc. Johnson Fincl invested in 0.01% or 1,072 shares. Stoneridge Investment Partners Llc sold 25,714 shares as Keycorp (KEY)'s stock declined 6.49%. Atlantic Trust Group LLC lifted its holdings in shares of Microchip Technology by 255.3% during the 3rd quarter. 10,638 are owned by Carnegie Cap Asset Mgmt Lc. Keybank Natl Association Oh holds 0.02% or 33,353 shares. Hall Laurie J Trustee invested in 0% or 56 shares. It dropped, as 40 investors sold PTEN shares while 64 reduced holdings. Sentinel Asset has invested 0.15% in Microchip Technology Incorporated (NASDAQ:MCHP). Washington National Bank & Trust reported 1,459 shares. Moreover, Timessquare Cap Ltd Liability Co has 0.48% invested in Microchip Technology Incorporated (NASDAQ:MCHP) for 805,300 shares. Public Employees Retirement Association Of Colorado reported 0.58% of its portfolio in Microchip Technology Incorporated (NASDAQ:MCHP). Zacks Investment Research raised shares of Microchip Technology from a "hold" rating to a "buy" rating and set a $102.00 target price on the stock in a research note on Friday, November 10th. Therefore 62% are positive. Microchip Technology had 70 analyst reports since August 5, 2015 according to SRatingsIntel. This is an increase from Microchip Technology's previous quarterly dividend of $0.36. The stock of Microchip Technology Incorporated (NASDAQ:MCHP) has "Buy" rating given on Tuesday, November 7 by Stifel Nicolaus. Jefferies has "Buy" rating and $68 target. (NYSE:MRC) has "Buy" rating given on Monday, November 6 by Cowen & Co. Stifel Nicolaus maintained Microchip Technology Incorporated (NASDAQ:MCHP) rating on Tuesday, March 6. Jefferies maintained the shares of PG in report on Tuesday, May 30 with "Buy" rating. Microchip Technology presently has a consensus rating of "Buy" and an average target price of $103.04. The firm earned "Equal-Weight" rating on Wednesday, December 13 by Morgan Stanley.

Since January 12, 2018, it had 0 insider purchases, and 1 insider sale for $5.57 million activity. Schomburger Jeffrey K sold $3.07M worth of The Procter & Gamble Company (NYSE:PG) on Thursday, February 15. 5,000 shares were sold by MEYERCORD WADE F, worth $474,590. Also, CEO Steve Sanghi sold 20,124 shares of the company's stock in a transaction on Tuesday, March 6th. CHAPMAN MATTHEW W sold $564,492 worth of stock. Ameriprise Financial Inc. lifted its holdings in shares of Microchip Technology by 20.3% during the 3rd quarter. Bank of America decreased their price objective on shares of Microchip Technology from $120.00 to $110.00 and set a buy rating on the stock in a research report on Wednesday, February 7th.

In related news, CFO James Eric Bjornholt sold 2,109 shares of the company's stock in a transaction on Thursday, February 22nd. Whitelaw Gary bought $99,820 worth of stock.

Investors sentiment increased to 1.15 in Q3 2017. Its down 0.15, from 1.15 in 2017Q2. 4,159 shares valued at $349,938 were sold by LITTLE MITCHELL R on Thursday, February 22. 17 funds opened positions while 60 raised stakes. 130,918 shares or 1.96% more from 128,404 shares in 2017Q2 were reported. Advsr Asset Mngmt Inc accumulated 19,598 shares. Gemmer Asset Management Ltd Company reported 282 shares stake. Neuberger Berman Group Ltd Liability Corporation has invested 0% in KeyCorp (NYSE:KEY). Bain Equity Mngmt Limited Co has invested 1.17% in KeyCorp (NYSE:KEY). Also, the Hold rating count is 0 as of 03/09/18.

Caxton Associates LP increased its position in shares of Microchip Technology Inc.

Tweedy Browne Company Llc increased its stake in Mrc Global Inc. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It primarily invests in the real estate markets of the United States. The stock price mounted 14.67% in three months and soared 13.25% for the last six months trading period. Patterson-UTI Energy, Inc. (NASDAQ:PTEN) has risen 32.91% since March 12, 2017 and is uptrending. It has underperformed by 61.19% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article